GlaxoSmithKline to buy vaccine developer with 'potentially disruptive technology' in deal worth up to $3.3B
May 31, 2022 at 12:15 PM EDT
The deal puts GSK in a stronger position to compete with Pfizer and Merck, which are also active in vaccine development.
